7BG Stock Overview
A clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BerGenBio ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.0096 |
| 52 Week High | kr0.03 |
| 52 Week Low | kr0.0001 |
| Beta | 1.44 |
| 1 Month Change | -15.04% |
| 3 Month Change | -37.25% |
| 1 Year Change | 9,500.00% |
| 3 Year Change | -99.57% |
| 5 Year Change | n/a |
| Change since IPO | -99.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7BG | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.0% | -1.6% | -0.5% |
| 1Y | 9,500.0% | -24.7% | 5.2% |
Return vs Industry: 7BG underperformed the German Biotechs industry which returned -24.7% over the past year.
Return vs Market: 7BG underperformed the German Market which returned 5.2% over the past year.
Price Volatility
| 7BG volatility | |
|---|---|
| 7BG Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 7BG's share price has been volatile over the past 3 months.
Volatility Over Time: 7BG's weekly volatility has decreased from 2012% to 11% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 16 | Martin Olin | www.bergenbio.com |
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma.
BerGenBio ASA Fundamentals Summary
| 7BG fundamental statistics | |
|---|---|
| Market cap | €42.56m |
| Earnings (TTM) | -€16.58m |
| Revenue (TTM) | €30.83k |
1,380x
P/S Ratio-2.6x
P/E RatioIs 7BG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7BG income statement (TTM) | |
|---|---|
| Revenue | kr354.00k |
| Cost of Revenue | kr0 |
| Gross Profit | kr354.00k |
| Other Expenses | kr190.76m |
| Earnings | -kr190.40m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 29, 2024
| Earnings per share (EPS) | -0.049 |
| Gross Margin | 100.00% |
| Net Profit Margin | -53,785.59% |
| Debt/Equity Ratio | 0% |
How did 7BG perform over the long term?
See historical performance and comparison